|Other Names||Max-interacting protein 1, Max interactor 1, Class C basic helix-loop-helix protein 11, bHLHc11, MXI1, BHLHC11|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Transcriptional repressor. MXI1 binds with MAX to form a sequence-specific DNA-binding protein complex which recognizes the core sequence 5'-CAC[GA]TG-3'. MXI1 thus antagonizes MYC transcriptional activity by competing for MAX.|
|Tissue Location||High levels found in the brain, heart and lung while lower levels are seen in the liver, kidney and skeletal muscle|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Expression of the c-myc gene, which produces an oncogenictranscription factor, is tightly regulated in normal cells but isfrequently deregulated in human cancers. The protein encoded bythis gene is a transcriptional repressor thought to negativelyregulate MYC function, and is therefore a potential tumorsuppressor. This protein inhibits the transcriptional activity ofMYC by competing for MAX, another basic helix-loop-helix proteinthat binds to MYC and is required for its function. Defects in thisgene are frequently found in patients with prostate tumors. Threealternatively spliced transcripts encoding different isoforms havebeen described. Additional alternatively spliced transcripts mayexist but the products of these transcripts have not been verifiedexperimentally.
Lofstedt, T., et al. Exp. Cell Res. 315(11):1924-1936(2009)Baranzini, S.E., et al. Hum. Mol. Genet. 18(4):767-778(2009)Tsao, C.C., et al. Cancer Biol. Ther. 7(10):1619-1627(2008)Suo, X.H., et al. Zhonghua Xue Ye Xue Za Zhi 28(11):745-749(2007)Dugast-Darzacq, C., et al. FEBS J. 274(17):4643-4653(2007)
If you have any additional inquiries please email technical services at email@example.com.